{"id":"low-molecule-heparin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"1-5","effect":"Injection site hematoma"},{"rate":"1-3","effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL4650299","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Low molecular weight heparin (LMWH) is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in smaller chain lengths. It binds to antithrombin III and potentiates its inhibition of factor Xa more selectively than factor IIa, providing predictable pharmacokinetics and a more favorable bleeding profile compared to unfractionated heparin. LMWH is used for both treatment and prevention of thrombotic events.","oneSentence":"Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:28.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention and treatment of deep vein thrombosis"},{"name":"Prevention and treatment of pulmonary embolism"},{"name":"Acute coronary syndrome"},{"name":"Thromboprophylaxis in surgical patients"}]},"trialDetails":[{"nctId":"NCT06079021","phase":"NA","title":"COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2024-06-08","conditions":"Acute-On-Chronic Liver Failure, Anticoagulant Adverse Reaction, Sarcopenia","enrollment":20},{"nctId":"NCT03812328","phase":"PHASE2","title":"Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement","status":"COMPLETED","sponsor":"Tetherex Pharmaceuticals Corporation","startDate":"2019-02-20","conditions":"Venous Thromboembolism","enrollment":207},{"nctId":"NCT04256525","phase":"PHASE4","title":"Prophylactic Anticoagulation for Catheter-related Thrombosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Venous Thrombosis Due to Central Venous Access Device (Disorder), Prophylactic Anticoagulation, Patients With Tumor","enrollment":1640},{"nctId":"NCT02091479","phase":"PHASE3","title":"Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2013-01","conditions":"Major hæmorrhage","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"low molecule heparin","genericName":"low molecule heparin","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa. Used for Prevention and treatment of deep vein thrombosis, Prevention and treatment of pulmonary embolism, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}